Clinical trial · Expanded Access
Expanded Access to Veliparib
NCT03123211CI-TRIAL-00058685no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Grade Serous Ovarian Cancer | High-Grade Serous Ovarian Cancer | ONTOLOGY_EXACT | 0.98 |
| Patients Requiring Veliparib Suspension Formulation | — | UNRESOLVED | — |
| Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound | — | UNRESOLVED | — |
| Triple Negative Breast Cancer (TNBC) | Triple-Negative Breast Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Veliparib | Drug | Veliparib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * The patient has relapsed/refractory disease and exhausted all standard treatments. * The patient has documented Breast Cancer (BRCA), BRCA associated RING domain (BARD), or Partner and Localizer of Breast Cancer (PALB) or other acceptable deoxyribonucleic acid (DNA) mutations. Exclusion Criteria: * The patient is eligible for a Poly Adenosine diphosphate ribose polymerase (PARP) inhibitor clinical trial. * The patient has previously received a PARP inhibitor for the same disease.
References
Publications (0)
Data not yet available
No reference posted for this study.